Synairgen Competitors and Similar CompaniesClear all

Synairgen's competitors and similar companies include BioMarker Strategies, NantHealth, Precision Diagnostics and M3.

	Synairgen Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic.	BioMarker Strategies BioMarker Strategies offers SnapPath, a live tumor cell testing platform that improves the treatment of cancer.	NantHealth NantHealth is a healthcare company providing an evidence-based platform for healthcare diagnostics.	Precision Diagnostics Precision Diagnostics is a clinical laboratory that provides precision testing, analytics, and billing services.	M3 M3 is a medical care services providing company.
Founding Date	Founding Date N/A	Founding Date 2007	Founding Date 2007	Founding Date 2013	Founding Date 2000
Type	Type Public	Type Private	Type Public	Type Private	Type Public
Tags	Tags Healthcare clinics drug development medical diagnostics platform	Tags Healthcare clinics medical diagnostics platform	Tags Healthcare clinics medical diagnostics platform	Tags Healthcare drug development medical diagnostics	Tags Healthcare drug development medical diagnostics
Locations	Locations Southampton, GB HQ	Locations Derwood, US HQ	Locations El Segundo, US HQ	Locations San Diego, US HQ Dartmouth, US	Locations Tokyo, JP HQ
Employees	Employees 36	Employees 3	Employees 36512% increase	Employees 261	Employees 12,100
Valuation ($)	Valuation ($) 12.4 m	Valuation ($) N/A	Valuation ($) 10.4 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $67m (FY, 2022)	Revenue (est.) N/A	Revenue (est.) ¥284.9b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods $28.8m (FY, 2022)	Cost of goods N/A	Cost of goods ¥128.9b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit $38.2m (FY, 2022)	Gross profit N/A	Gross profit ¥156.8b (FY, 2025)
Net income	Net income (£6.8m) (FY, 2024)	Net income N/A	Net income ($67.8m) (FY, 2022)	Net income N/A	Net income ¥44.3b (FY, 2025)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 5.7m	Total funding raised $ 547.5m	Total funding raised N/A	Total funding raised N/A